Prevention, treatment and control of CBPP in cattle

Prevention, treatment and control of CBPP in cattle Contagious bovine pleuropneumonia (CBPP) is an insidious pneumonic disease of cattle sometimes refer
(1)

Contagious bovine pleuropneumonia (CBPP) is one of the great plagues which continue to devastate cattle herds on which so many people are dependent in Africa. In recent years the disease has emerged from areas where it has been persisting in endemic form to reinvade others from which it had previously been eradicated. In addition to these newly-infected areas, even the endemic areas are experienci

ng an upsurge in the incidence of CBPP. Recent dramatic events confirm that early recognition of the disease after its introduction or reintroduction to a country, or previously free zone of an infected country, is essential if control and elimination is to be achieved rapidly. Only if the introduction is detected rapidly can stamping out by slaughter of infected herds, undoubtedly the most cost-effective option in the long term, be considered an affordable strategy for many countries. Because of the nature of the disease any delay can result in widespread dispersal of infection complicating and greatly increasing the costs of any control measures adopted. Vigilance is required whether it be at the national or district level to ensure that the disease does not escape detection. This manual presents the most important features of CBPP to enable the disease to be recognised both by clinical and post-mortem examination. It is intended for use by all veterinary and paraveterinary staff in the front line of defence against the disease and also to assist in informing farmers of the risk.

03/02/2023
Infection spreads by aerosol from cough, by direct contact with infected animals, or through placenta to the unborn calf...
14/01/2023

Infection spreads by aerosol from cough, by direct contact with infected animals, or through placenta to the unborn calf. Fomites are not a major source of transmission.

Clinical signs
The incubation period is one to three months. A few cattle may die of peracute disease with no symptoms other than fever. Acute symptoms include fever, lethargy, cough, extended necks and laboured breathing, and loss of appetite and milk production. Calves may develop arthritis and lameness. After initial acute faze, the infection often becomes chronic.

Control
Outbreaks are eradicated with quarantines, slaughter of infected and in-contact animals, and cleaning and disinfection. Vaccines are available and have helped to control the disease in endemic areas.

CBPP is endemic in Africa in areas between the Tropic of Cancer and the Tropic of Capricorn.Impact CBPP can cause loses ...
14/01/2023

CBPP is endemic in Africa in areas between the Tropic of Cancer and the Tropic of Capricorn.

Impact
CBPP can cause loses from 20% to up to 80%. Morbidity and mortality vary between different pathogen strains. Contagious Bovine Pleuropneumonia (CBPP) affects 27 countries in Africa at an estimated annual cost of US $2 billion.

A live, attenuated vaccine is currently the only viable option to control of CBPP in Africa. It has been suggested that ...
06/10/2022

A live, attenuated vaccine is currently the only viable option to control of CBPP in Africa. It has been suggested that simple modifications to current vaccines and protocols might improve efficacy in the field. In this report we compared the current vaccine formulation with a buffered preparation that maintains Mycoplasma viability at ambient temperature for a longer time. Groups of animals were vaccinated with the two formulations and compared with non vaccinated groups. Half of the animals in each group were challenged 3 months post vaccination, the other half after 16 months. Protection levels were measured using the pathology index, calculated from post mortem scores of lesions from animals killed during the course of clinical disease. In the challenge at 3 months post vaccination, the protection levels were 52% and 77% for the modified and current vaccine preparations, respectively. At 16 months post vaccination, the protection levels were 56% and 62% for the modified and current vaccine preparations, respectively. These findings indicate that there are no differences in protection levels between the two vaccines. Because of its longer half life after reconstitution, the modified vaccine might be preferred in field situations where the reconstituted vaccine is likely not to be administered immediately.

Contagious bovine pleuropneumonia (CBPP) vaccines are routinely used only in Africa. The vaccines are usually produced f...
06/10/2022

Contagious bovine pleuropneumonia (CBPP) vaccines are routinely used only in Africa. The vaccines are usually produced from one of two strains (T1/44 and KH3J), each of which has a streptomycin-resistant variant. The necessity for a 'master seed strain' is evident. At least one manufacturer in Africa produces a broth culture vaccine, while others produce a freeze-dried product. A standardised manufacturing protocol needs to be developed, together with in-process and final product quality control procedures. Some CBPP vaccine manufacturing procedures do not allow sufficient leeway for the ex*****on of typical quality control practices. For example, it is difficult to perform batch testing on broth culture vaccine, as the vaccine is produced in its final container. Quality control test results from the Pan African Veterinary Vaccine Centre (PANVAC) are analysed in terms of causes of batch failure and indicators for process development. Taking potency as an example, most vaccine batches tested by PANVAC pass only at the limit of the OIE minimum requirement of 10(7) colony-forming units per dose. To improve the titre of the vaccine, it will be necessary to modify the manufacturing process, either by increasing mycoplasma yield during the culture phase or by minimising losses during downstream processes, especially freeze-drying. Data on inactivated vaccines are scarce. Duration of the immunity achieved with live CBPP vaccines is relatively short, in comparison with other live vaccines. Data may be required on the molecular basis of virulence and immunogenicity, as well as on the molecular immunology of CBPP, to enable the development of improved vaccines.

The disease is reportable by law in many countries from which it has been eradicated by slaughter of all infected and ex...
09/09/2022

The disease is reportable by law in many countries from which it has been eradicated by slaughter of all infected and exposed animals. In countries where cattle movement can readily be restricted, the disease can be eradicated by quarantine, blood testing, and slaughter. Where cattle cannot be confined, the spread of infection can be limited by immunization with attenuated vaccine (eg, T1/44 strain). However, the vaccine is effective only if herd coverage within a country is high. Tracing the source of infected cattle detected at abattoirs, blood testing, and imposition of strict rules for cattle movement also can aid in control of the disease in such areas.

Treatment is recommended only in endemic areas because the organisms may not be eliminated, and carriers may develop. Ty...
09/09/2022

Treatment is recommended only in endemic areas because the organisms may not be eliminated, and carriers may develop. Tylosin (10 mg/kg, IM, bid, for six injections) and danofloxacin 2.5% (2.5 mg/kg/day for 3 consecutive days) have been reported to be effective.

13/07/2022

Contagious bovine pleuropneumonia (CBPP) and contagious caprine pleuropneumonia (CCPP) are major infectious diseases of ruminants caused by mycoplasmas in Africa and Asia. In contrast with the limited pathology in the respiratory tract of humans infected with mycoplasmas, CBPP and CCPP are devastating diseases associated with high morbidity and mortality. Beyond their obvious impact on animal health, CBPP and CCPP negatively impact the livelihood and wellbeing of a substantial proportion of livestock-dependent people affecting their culture, economy, trade and nutrition. The causative agents of CBPP and CCPP are Mycoplasma mycoides subspecies mycoides and Mycoplasma capricolum subspecies capripneumoniae, respectively, which have been eradicated in most of the developed world. The current vaccines used for disease control consist of a live attenuated CBPP vaccine and a bacterin vaccine for CCPP, which were developed in the 1960s and 1980s, respectively. Both of these vaccines have many limitations, so better vaccines are urgently needed to improve disease control. In this article the research community prioritized biomedical research needs related to challenge models, rational vaccine design and protective immune responses. Therefore, we scrutinized the current vaccines as well as the challenge-, pathogenicity- and immunity models. We highlight research gaps and provide recommendations towards developing safer and more efficacious vaccines against CBPP and CCPP.

04/04/2022
04/04/2022

Contagious bovine plueuropneumonia is highly contagious and generally accompanied by pleurisy. It is present in Africa, with minor outbreaks occurring in the Middle East. The USA has been free of the disease since 1892, the UK since 1898, and Australia since 1973. The last outbreak of CBPP in Europe was seen in Portugal in 1999. Little is known about the disease in Asia, but China claims that its last outbreak was in 1995.
Etiology:
The causal organism is Mycoplasma mycoides mycoides small colony type. (Also see Contagious Caprine Pleuropneumonia.) Susceptible cattle become infected by inhaling droplets disseminated by coughing in affected cattle. Small ruminants and wildlife are not important in the epidemiology. Sheep and goats can be naturally infected but have no associated pathology. The organism can also be found in saliva, urine, fetal membranes, and uterine discharges. Transplacental infection of the fetus can occur. Viability of the organism in the environment is poor. The incubation period varies, but most cases occur 3–8 wk after exposure. In some localities, susceptible herds may show up to 70% morbidity, but much lower infection rates (~10%) associated with clinical signs are more common. Mortality is likely to be ~50% in herds experiencing the disease for the first time. Of recovered animals, 25% may become carriers with chronic lung lesions in the form of sequestra of variable size. Because carriers may not be detectable clinically or serologically, they constitute a serious problem in control programs. Breed susceptibility, management systems, and general health of the animal are important factors that influence the infection.
Clinical Findings:
In acute cases, signs include fever up to 107°F (41.5°C); anorexia; and painful, difficult breathing. In hot climates, the animal often stands by itself in the shade, its head lowered and extended, its back slightly arched, and its elbows turned out. Percussion of the chest is painful; respiration is rapid, shallow, and abdominal. If the animal is forced to move quickly, the breathing becomes more distressed and a soft, moist cough may result. The disease progresses rapidly, animals lose condition, and breathing becomes very labored, with a grunt at expiration. The animal becomes recumbent and dies after 1–3 wk. Chronically affected cattle usually exhibit signs of varying intensity for 3–4 wk, after which the lesions gradually resolve and the animals appear to recover. Subclinical cases occur and may be important as carriers. Infected calves may present primarily with polyarthritis that is seen as swelling of joints and lameness.
Lesions:
The thoracic cavity may contain up to 10 L of clear yellow or turbid fluid mixed with fibrin flakes, and the organs in the thorax are often covered by thick deposits of fibrin. The disease is largely unilateral, with more than 80%–90% of cases affecting only one lung. The affected portion is enlarged and solid. On section of the lung, the typical marbled appearance of pleuropneumonia is evident because of the widened interlobular septa and subpleural tissue that encloses gray, yellow, or red consolidated lung lobules. Microscopically, this is a severe, acute, fibrinous pneumonia with fibrinous pleurisy, thrombosis of pulmonary blood vessels, and areas of necrosis of lung tissue; the interstitial tissue is markedly thickened by edema fluid containing much fibrin. In chronic cases, the lesion has a necrotic center sequestered in a thick, fibrous capsule, and there may be fibrous pleural adhesions. Organisms may survive only within the inner capsule of these sequestra, and these animals may become carriers.
Diagnosis:
Diagnosis is based on clinical signs and the characteristic gross pathologic lesions of the lungs. Complement fixation, latex agglutination, or competitive ELISA tests can be used to aid definitive diagnosis. Confirmation is often by isolation of the mycoplasma followed by growth inhibition or immunofluorescence test using hyperimmune rabbit sera against the mycoplasma, or increasingly by PCR. Confirmation of serologic reactions can be made by immunoblotting test. As soon as an outbreak is suspected, slaughter and necropsy of presumptively infected cattle is advisable.
Control:
The disease is reportable by law in many countries from which it has been eradicated by slaughter of all infected and exposed animals. In countries where cattle movement can readily be restricted, the disease can be eradicated by quarantine, blood testing, and slaughter. Where cattle cannot be confined, the spread of infection can be limited by immunization with attenuated vaccine (eg, T1/44 strain). However, the vaccine is effective only if herd coverage within a country is high. Tracing the source of infected cattle detected at abattoirs, blood testing, and imposition of strict rules for cattle movement also can aid in control of the disease in such areas.
Treatment is recommended only in endemic areas because the organisms may not be eliminated, and carriers may develop. Tylosin (10 mg/kg, IM, bid, for six injections) and danofloxacin 2.5% (2.5 mg/kg/day for 3 consecutive days) have been reported to be effective.

Contagious bovine pleuropneumonia (CBPP) is an insidious pneumonic disease of cattle sometimes refer

The DiseaseContagious bovine pleuropneumonia (CBPP) is an insidious pneumonic disease of cattle sometimes referred to as...
18/05/2021

The Disease
Contagious bovine pleuropneumonia (CBPP) is an insidious pneumonic disease of cattle sometimes referred to as lung sickness. Clinically, CBPP is manifested by anorexia, fever and respiratory symptoms such as dyspnoea, cough and nasal discharges. CBPP is found in the acute, subacute and chronic forms.

The disease is characterized by the presence of sero-fibrinous interlobular oedema and hepatization giving a marbled appearance of the lung in acute to subacute cases, and capsulated lesions (sequestra) in the lungs of some chronically infected cattle. Joint infections are common in calves.

The causative agent of CBPP is Mycoplasma mycoides subspecies mycoides small colony variant (MmmSC). Phylogenetically, the organism is a member of the Mycoplasma mycoides cluster which are pathogens of ruminants and include M. mycoides subsp. mycoides large colony (LC), M. mycoides subsp. capri, M. capricolum subsp. capripneumoniae, M. capricolum subsp. capricolum and Mycoplasma bovine group 7, an unnamed group of bovine mycoplasma isolates. The occurrence of subacute symptomless infections and chronic carriers after the clinical phase of the disease, create major problems in the control of this disease.

Geographical Distribution
CBPP is present in Africa, the Middle East, parts of Asia and until recently, in the Iberian Peninsula of southern Europe. In Africa, the disease is found in an area south of the Sahara, from the Tropic of Cancer to the Tropic of Capricorn and from the Atlantic to the Indian Ocean. Endemic infection extends throughout the pastoral herds of much of western, central and eastern Africa, and in Angola and northern Namibia in southern Africa.

In accordance with the OIE procedure for official recognition of disease status, this page provides access to the List o...
23/04/2021

In accordance with the OIE procedure for official recognition of disease status, this page provides access to the List of OIE Members officially recognised free from contagious bovine pleuropneumonia (CBPP) by the OIE through the adoption of a resolution by the World Assembly of Delegates (Assembly) of the OIE at the General Session in May every year.
A Member wishing to be officially recognised as disease-free by the OIE should submit the questionnaire laid out in Chapter 1.6. of the OIE Terrestrial Animal Health Code (Terrestrial Code) and comply with all requirements specified in the Terrestrial Code for CBPP. The OIE Scientific Commission for Animal Diseases (Scientific Commission) is responsible for undertaking, on behalf of the Assembly, the assessment of OIE Members' applications for their compliance with OIE standards. The assessment carried out by the Scientific Commission is based on the recommendations formulated by a relevant ad hoc Group composed of world specialists in disease control.
Subsequent to a disease outbreak or when the Scientific Commission determines that the conditions are not met anymore to demonstrate compliance with the relevant requirements of the Terrestrial Code, a disease status may be suspended. The Scientific Commission may decide to reinstate the suspended status when a Member has submitted an application which fulfils all the requirements requested for the recovery of official disease status laid out in the relevant Chapters of the Terrestrial Code. The suspensions and recoveries of disease status are announced by the Director General of the OIE in consultation with the Scientific Commission and the list of these is kept up to date until adoption of a new resolution by the Assembly the following May.
Members with a disease free status officially recognised by the OIE must submit an annual reconfirmation form by the end of November every year.

One of the three great historic cattle plagues of the world, (along with Foot and Mouth Disease and Rinderpest), CBPP wa...
23/04/2021

One of the three great historic cattle plagues of the world, (along with Foot and Mouth Disease and Rinderpest), CBPP was first recognized in Germany in 1693. The history of its introduction to countries and subsequent eradication often parallels the development of veterinary services.
The USA has been free of the disease since 1892, the UK since 1898, Zimbabwe since 1904, South Africa (where the disease was introduced by the importation of infected bulls from Holland in 1853) since 1924, Australia since 1970s and China since the 1980s.
After its elimination from Europe in the nineteenth century, the disease reappeared in Portugal and Spain in 1951 and 1957, respectively. A few outbreaks were reported in southern France, the latest in 1984. In Italy, the disease reappeared in 1990 but was eliminated by 1993, and the last case in Europe was in Portugal in 1999.


What is Contagious bovine pleuropneumonia?
Contagious bovine pleuropneumonia (CBPP) is a disease of cattle and water buffalo caused by Mycoplasma mycoides subsp. Mycoides (M. mycoides). As the name suggests, it attacks the lungs and the membranes that line the thoracic cavity (the pleura) causing fever and respiratory signs such as laboured or rapid respiration, cough and nasal discharges.
Because it is highly contagious with a mortality rate of up to 50%, it causes significant economic losses. CBPP is a prominent cattle disease in Africa.
CBPP is a disease listed by the OIE in the Terrestrial Animal Health Code. Member countries are obligated to report occurrences of the disease according to the standards in the OIE Terrestrial Animal Health Code.
CBPP is one of the diseases for which the OIE has . The OIE Terrestrial Animal Health Code specifies the steps a country must follow in order to be officially recognized by the OIE as free of CBPP.
Transmission and spread
Transmission of the disease occurs through direct contact between an infected and a susceptible animal which becomes infected by inhaling droplets disseminated by coughing. Since some animals can carry the disease without showing signs of illness, controlling the spread is more difficult.
There is no evidence of transmission through fomites (inanimate objects such as clothing, implements or vehicles) as the organism does not persist in the environment.
Public health risk
Humans are not known to be susceptible to contagious bovine pleuropneumonia, so there is no public health risk.
Clinical signs
CBPP is manifested by loss of appetite, fever and respiratory signs, such as rapid respiratory rate, cough and nasal discharges and painful, difficult breathing. In hot climates, an affected animal often stands by itself in the shade, its head lowered and extended, its back slightly arched, and its limbs turned out. In many cases, the disease progresses rapidly, animals lose condition, and breathing becomes very laboured, with a grunt at expiration. The animals become recumbent (lie down) and in severe cases die after 1-3 wk.
The mortality rate may be as high as 50% in the absence of antibiotic treatment. However, clinical signs are not always evident. Subacute or asymptomatic forms can occur as affected animals partially recover after a period of three to four weeks. However, these cattle may be capable of spreading the disease, acting as unapparent carriers.
Diagnostic
The diagnosis is based on isolation of M. mycoides from samples such as nasal swabs and/or lung washings or pleural fluid obtained by puncture, or necropsy samples. The details the diagnostic procedures for CBPP
Prevention and control
The main problems for control or eradication are the frequent occurrence of subacute or unapparent infections and the persistence of chronic carriers after the clinical phase.
In most continents, control strategies are based on the early detection of outbreaks, control of animal movements and a stamping-out policy. This has successfully eliminated the disease from North America and Europe. In Africa control of the disease is currently based mainly on vaccination campaigns.
Surveillance of the disease through slaughterhouse inspection is a very efficient method of detecting clinical cases.
Treatment of affected animals with antibiotics can result in healthy looking animals that are still infected and able to spread the disease, so it is not recommended.
Vaccination with an attenuated strain of the bacteria is used to reduce the level of infection. Vaccine is produced following the guideline in the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals.
Geographical distribution
CBPP was known in Europe as early as the 16th century. It was spread throughout the world by increased international trade in live cattle in the second half of the 19th century. Stamping out policy eradicated the disease from many countries; however it currently persists in sub-Saharan Africa.

21/04/2021

Contagious bovine pleuropneumonia (CBPP) is an infectious and contagious respiratory disease of cattle, caused by Mycoplasma mycoides subsp. mycoides (Mmm). In this review, basic epidemiological features of CBPP, complicated by existing different strains of Mycoplasmas with similar biochemical characteristics, with preference to Sub-Saharan Africa are discussed. Many sub-Saharan African countries are challenged by variable gaps that include diagnostic tools and control strategies. Science-based issues on diagnostic procedures, vaccination, treatment, and other control strategies are discussed. Participatory epidemiology (PE), a diagnostic technique used in the identification and solving of animal health problems in rural communities, was also discussed. PE application, in conjunction with conventional diagnostic tools, will improve CBPP identification in pastoral rural communities and promote control of the disease in Africa. Furthermore, adequate CBPP control can be achieved through stronger political commitments from governments by prioritizing the disease among major diseases of high economic importance to the livestock industry for surveillance and control. Investment in CBPP control in endemic African countries will assure food security, livelihoods and the general well-being of people, and international trade.

Keywords: contagious bovine pleuropneumonia, Mycoplasma mycoides subsp. mycoides, economic impact, diagnostic tools, control strategies, sub-Saharan Africa

Address

Adama
ADAMA

Telephone

+251916760076

Website

Alerts

Be the first to know and let us send you an email when Prevention, treatment and control of CBPP in cattle posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Prevention, treatment and control of CBPP in cattle:

Videos

Share

Category